Cambios inducidos en DKK1 en pacientes con artritis reumatoide que inician tratamiento con terapia biológica

Palma-Sánchez, D.; Haro-Martínez, AC; Muñoz, Ignacio; Torre, M. Portero de la; González, Marta Mayor; Peñas, Elena; Reyes-García, Rebeca

doi:10.4321/s1889-836x2016000100005

Cited by 5 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our preliminary study showed a decrease in DKK1 levels after 6 months of treatment 26 , which was in agreement with that published by Briot et al 13 . In this article, patients with active RA treated with tocilizumab experienced a decrease in DKK1 concentrations, as well as a decrease in markers of bone formation at 3 and 12 months of treatment, not finding changes in the levels of sclerostin.…”

Section: Discussionsupporting

confidence: 94%

Efecto de la terapia biológica en las concentraciones de DKK1 y esclerostina, riesgo cardiovascular y metabolismo óseo en pacientes con artritis reumatoide

Palma-Sánchez

Haro-Martínez

Muñoz

et al. 2018

Rev Osteoporos Metab Miner

View full text Add to dashboard Cite

Introduction: Previous studies have linked the Wnt pathway in the alteration of bone metabolism and cardiovascular pathology. Also, the control of inflammation with biological therapy has a positive effect on bone mineral density (BMD) and cardiovascular risk. The aim of the study was to evaluate the effect of biological therapy in patients with rheumatoid arthritis, naïve to these therapy, on the inflammatory load and its relation with cardiovascular risk and bone metabolism. Patients and methods: Prospective cohort study performed in patients diagnosed with active rheumatoid arthritis (RA) initiating biological therapy. Patients were selected consecutively not selected. The serum concentrations of Dickkopf-1 protein (DKK1) and sclerostin were collected, both by means of the ELISA method (Biomedica Medizinprodukte GmbH and Co. KG, Vienna, Austria); demographic and clinical variables, markers of bone remodeling, hip and lumbar spine BMDs were measured by dual energy X-ray absorptiometry (DXA), measurement of intima-media thickness (IMT), evaluation cardiovascular risk by Systematic Coronary Risk Evaluation (SCORE). Results: 46.7% of patients presented EULAR response to treatment at 12 months. Only in this subgroup of patients, we found in the subgroup of patients an increase in the concentrations of DKK1 following the initiation of biological therapy (baseline 20.55±8.13 pg/ml vs 12 months 31.20±4.88 pg/ml, p=0.03). Regarding markers of bone remodeling, an increase in osteocalcin levels (baseline: 11.25±3.28 ng/ml vs 12 months 15.78±4.11 ng/ml, p=0.01). There was no change in IMT or SCORE at 12 months of treatment. Conclusions: In patients with RA treated with biological therapy who presented EULAR response we observed a significant increase in serum concentrations of DKK1 at 12 months of treatment not associated with changes in bone metabolism and cardiovascular risk.

show abstract

Section: Discussionsupporting

confidence: 94%

Efecto de la terapia biológica en las concentraciones de DKK1 y esclerostina, riesgo cardiovascular y metabolismo óseo en pacientes con artritis reumatoide

Palma-Sánchez

Haro-Martínez

Muñoz

et al. 2018

Rev Osteoporos Metab Miner

View full text Add to dashboard Cite

show abstract

Dickkopf 1 protein circulating levels as a possible biomarker of functional disability and chronic damage in patients with rheumatoid arthritis

et al. 2017

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an inflammatory disease characterized by joint destruction, deformity, lower functionality, and decrease in life expectancy. Wingless signaling pathway (Wnt) has been recently involved in bone homeostasis. Studies suggest that overexpression of the pathway inhibitors, like the Dickkopf 1 protein (DKK1), has been implicated in bone destruction. The objective of this study is to compare circulating levels of DKK1 in different groups of patients with disease activity (remission, low, moderate, high activity,) and functionality status. Three hundred seventy-nine patients with RA were evaluated between March 2015 and November 2016. Disease activity was evaluated by disease activity score 28 with C-reactive protein (DAS28CPR), simplified and clinical disease activity scores (SDAI, CDAI), routine assessment of patient index data 3 (RAPID3), functional status using Multidimensional Health Assessment Questionnaire (MD-HAQ), and the Steinbrocker functional classification. DKK1 levels were measured by ELISA. The mean age was 60.7 ± 13.9 years. Disease duration was 13.2 ± 10.9 years. Higher levels of DKK1 were not associated with disease activity by CDAI (p = 0.70), SDAI (p = 0.84), DAS28CRP (p = 0.80), or RAPID3 (p = 0.70). Interestingly higher levels of DKK1 were significantly associated to lower functional status evaluating by the Steinbrocker classification (p = 0,013), severe disability by MD-HAQ (p = 0,004), and variables associated with joint destruction like osteoporosis, higher titles of rheumatoid factor, smoking, and increased hospital admissions related to RA. Higher levels of DKK1 were found in patients with lower functional status. This association was not found in patients with greater disease activity by CDAI, SDAI, DAS28, and RAPID3. This could be explained by more structural damage; DKK1 could be used as a biomarker of joint destruction in RA.

show abstract

Proteína Dickkopf 1 y deterioro osteoarticular en artritis reumatoide: revisión sistemática

Cardona-Rincón

Bello-Gualtero

Munévar-Niño

et al. 2019

Revista Colombiana de Reumatología

View full text Add to dashboard Cite

Cambios inducidos en DKK1 en pacientes con artritis reumatoide que inician tratamiento con terapia biológica

Cited by 5 publications

References 17 publications

Efecto de la terapia biológica en las concentraciones de DKK1 y esclerostina, riesgo cardiovascular y metabolismo óseo en pacientes con artritis reumatoide

Efecto de la terapia biológica en las concentraciones de DKK1 y esclerostina, riesgo cardiovascular y metabolismo óseo en pacientes con artritis reumatoide

Dickkopf 1 protein circulating levels as a possible biomarker of functional disability and chronic damage in patients with rheumatoid arthritis

Proteína Dickkopf 1 y deterioro osteoarticular en artritis reumatoide: revisión sistemática

Contact Info

Product

Resources

About